Zacks Investment Research upgraded shares of Savara (NASDAQ:SVRA) from a hold rating to a buy rating in a research note published on Thursday morning, Zacks.com reports. Zacks Investment Research currently has $12.00 target price on the stock.
According to Zacks, “Savara Inc. is a clinical-stage pharmaceutical company. It focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Savara Inc., formerly known as Mast Therapeutics, Inc., is based in Austin, United States. “
A number of other research analysts have also issued reports on the company. BidaskClub lowered Savara from a sell rating to a strong sell rating in a research report on Saturday, January 19th. Canaccord Genuity set a $22.00 target price on Savara and gave the company a buy rating in a research note on Monday, March 25th. LADENBURG THALM/SH SH restated a buy rating and issued a $21.00 target price on shares of Savara in a research note on Monday, April 1st. ValuEngine upgraded Savara from a sell rating to a hold rating in a research note on Monday, April 1st. Finally, Roth Capital set a $10.00 target price on Savara and gave the company a hold rating in a research note on Tuesday. Three analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. Savara presently has an average rating of Buy and a consensus price target of $21.17.
SVRA traded down $0.06 during mid-day trading on Thursday, reaching $11.64. The stock had a trading volume of 6,963 shares, compared to its average volume of 336,949. The firm has a market capitalization of $405.24 million, a price-to-earnings ratio of -8.97 and a beta of 1.07. The company has a debt-to-equity ratio of 0.24, a quick ratio of 15.63 and a current ratio of 12.05. Savara has a 52 week low of $6.21 and a 52 week high of $14.06.
Savara (NASDAQ:SVRA) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.34) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.39) by $0.05. As a group, research analysts forecast that Savara will post -1.6 EPS for the current year.
In other news, Director Richard J. Hawkins sold 25,000 shares of the company’s stock in a transaction dated Wednesday, May 15th. The stock was sold at an average price of $11.10, for a total transaction of $277,500.00. Following the completion of the sale, the director now owns 21,682 shares in the company, valued at approximately $240,670.20. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, COO Jaakko Taneli Jouhikainen sold 7,815 shares of the company’s stock in a transaction dated Thursday, April 4th. The stock was sold at an average price of $9.00, for a total value of $70,335.00. Following the sale, the chief operating officer now owns 184,754 shares of the company’s stock, valued at approximately $1,662,786. The disclosure for this sale can be found here. Insiders sold 75,261 shares of company stock worth $744,174 in the last 90 days. Corporate insiders own 6.50% of the company’s stock.
Large investors have recently made changes to their positions in the stock. FMR LLC acquired a new position in Savara in the 4th quarter valued at approximately $2,830,000. Vanguard Group Inc raised its holdings in shares of Savara by 23.6% in the 3rd quarter. Vanguard Group Inc now owns 1,246,240 shares of the company’s stock worth $13,908,000 after buying an additional 238,358 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Savara by 23.6% in the 3rd quarter. Vanguard Group Inc. now owns 1,246,240 shares of the company’s stock worth $13,908,000 after buying an additional 238,358 shares in the last quarter. BlackRock Inc. raised its holdings in shares of Savara by 8.2% in the 3rd quarter. BlackRock Inc. now owns 2,170,294 shares of the company’s stock worth $24,220,000 after buying an additional 164,056 shares in the last quarter. Finally, Morgan Stanley raised its holdings in shares of Savara by 224.1% in the 3rd quarter. Morgan Stanley now owns 205,560 shares of the company’s stock worth $2,294,000 after buying an additional 142,140 shares in the last quarter. Hedge funds and other institutional investors own 47.99% of the company’s stock.
Savara Company Profile
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Further Reading: How much can an individual set aside as a catch-up contribution?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.